Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4602 in HER2 expressing or mutated advanced solid tumors
NCT05819684Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-4602 in solid tumor (advanced stage) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Incidence and severity of adverse events (AEs), Maximum tolerated dose and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
SHR-4602
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05819684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819684.